Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:20:07 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:TVTX - TRAVERE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TVTX - Q0.114.74·18.450.116.11-0.40-2.41,443.822,74915,37716.65  16.74  16.1025.29  7.93116:33:14Jul 1115 min RT 2¢

Recent Trades - Last 10 of 15377
Time ETExPriceChangeVolume
16:33:14Q16.11-0.40671
16:20:00Q16.11-0.40462
16:04:02Q16.11-0.401
16:02:23Q16.11-0.40665
16:02:19Q16.11-0.40285
16:02:05Q16.11-0.4022
16:01:51Q16.11-0.40235
16:01:22Q16.11-0.40690
16:01:00Q16.11-0.40784
16:00:13Q16.11-0.408,392

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-11 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-12 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-11 07:01U:TVTXNews ReleaseTravere Therapeutics to Present New FILSPARI(TM) (sparsentan) Data at the 15th International Podocyte Conference
2025-06-10 07:00U:TVTXNews ReleaseTravere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
2025-06-03 16:30U:TVTXNews ReleaseTravere Therapeutics to Present New FILSPARI(TM) (sparsentan) Data at the 62nd ERA Congress
2025-05-23 04:00U:TVTXNews ReleaseEngland's NICE recommends FILSPARI(TM) (sparsentan) as a treatment option for IgA nephropathy
2025-05-15 16:05U:TVTXNews ReleaseTravere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI(TM) (sparsentan) in FSGS
2025-05-13 16:05U:TVTXNews ReleaseVerrica Pharmaceuticals Reports Quarterly 2025 Financial Results
2025-05-12 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-07 16:30U:TVTXNews ReleaseTravere Therapeutics to Participate at Upcoming Investor Conferences
2025-05-01 16:01U:TVTXNews ReleaseTravere Therapeutics Reports First Quarter 2025 Financial Results
2025-04-29 07:01U:TVTXNews ReleaseTravere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI(TM) (sparsentan) for IgA Nephropathy
2025-04-29 02:00U:TVTXNews ReleaseCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI(TM) in IgA Nephropathy
2025-04-24 16:30U:TVTXNews ReleaseTravere Therapeutics to Report First Quarter 2025 Financial Results
2025-04-11 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-31 16:30U:TVTXNews ReleaseTravere Therapeutics to Present New FILSPARI(TM) (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
2025-03-17 07:01U:TVTXNews ReleaseTravere Therapeutics Submits sNDA to FDA for Approval of FILSPARI(TM) (sparsentan) for the Treatment of FSGS
2025-03-12 17:30U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-24 16:30U:TVTXNews ReleaseTravere Therapeutics to Participate at Upcoming Investor Conferences
2025-02-20 16:01U:TVTXNews ReleaseTravere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results